A recent 6-year checkup on boys treated with gene therapy for cerebral adrenoleukodystrophy (CALD) reveals lasting benefits for most patients. CALD is a rare, severe brain disease that primarily affects young boys, often leading to a rapid decline in neurological function. In this follow-up, most patients showed stable brain function and minimal disabilities, showcasing the potential of gene therapy to bring hope to families facing this devastating diagnosis.

A Closer Look at CALD and Gene Therapy

CALD is caused by a mutation in the ABCD1 gene, which disrupts the body’s ability to break down certain fatty acids, leading to inflammation and progressive brain damage. The eli-cel gene therapy aims to correct this by delivering a healthy ABCD1 gene through a lentiviral vector. This approach allows patients’ own blood stem cells to produce the corrected gene, helping to restore nerve function and reduce disease progression.

Different Outcomes for Different Age Groups

The study highlighted differences in responses based on patient age groups:

- Younger Patients (Ages 3-7): These patients generally had the most positive results, with minimal signs of disability or neurological decline. The earlier intervention provided their brains with the best chance to adapt and maintain normal function.

- Older Patients (Ages 8-13): Although many older boys also benefited, some showed mild disabilities, likely due to longer exposure to disease progression before receiving treatment. However, even in this group, most maintained stable brain function and significantly improved quality of life compared to untreated CALD cases.

Lentiviral Vector Risks: A Word of Caution

While the overall results are promising, researchers observed a small number of cases (6 out of 35 patients) developing blood cancers, such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). These cases appear to be linked to the lentiviral vector used to deliver the gene therapy, emphasizing the need for careful monitoring and continued research to refine vector safety.

Balancing Hope and Safety

This 6-year follow-up reaffirms the potential of gene therapy to transform lives for CALD patients, particularly when administered at younger ages. However, the rare occurrence of cancer underscores the importance of ongoing monitoring and improvements in gene therapy technology. By balancing hope with caution, researchers are working tirelessly to ensure that future therapies can safely and effectively support all CALD patients and their families.

Gene therapy is a continuously evolving field, and with each milestone, researchers come closer to a safer, more accessible future for those battling rare genetic diseases.

Created: Oct 20th, 2024

Citations:

HealthDay. (2024, October 10). Boys treated with gene therapy for rare brain disease doing well 6 years later. U.S. News & World Report. https://www.usnews.com/news/health-news/articles/2024-10-10/boys-treated-with-gene-therapy-for-rare-brain-disease-doing-well-6-years-later

Keep exploring with Gene Tech Times

• Free guide: subscribe to the Gene Tech Times Briefing on our homepage and get Every FDA-Approved Gene Therapy at a Glance in your inbox.

• Watch: 30-second gene therapy Shorts on Gene Tech Times Academy.

• Read: The Cheat Codes of Our Genes, real stories of mutations that make some people immune to disease.

• New to gene therapy? Start with The Life-Changing Power of Gene Therapy.

As an Amazon Associate, Gene Tech Times earns from qualifying purchases.